Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Pipeline Snapshot as of July 28, 2021

  • Discovery Projects
  • Phase 1
    29
  • Phase 2
    40
  • Phase 3
    23
  • Registration
    8
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (E.U.) Registration Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor
1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Erbitux® (cetuximab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor and anti EGFR
Go to clinical trial
1st line BRAF-mutant Metastatic Colorectal Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
recifercept
Therapeutic Area:
Rare Diseases
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy
Achondroplasia (Biologic) (ORPHAN - U.S.) Phase 2 New Molecular Entity Biologic
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Biologic
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1 Inhibitor
Alopecia Areata Phase 2 Product Enhancement Small Molecule
ritlecitinib (PF-06651600)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC Inhibitor
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ankylosing Spondylitis (U.S., E.U.) Registration Product Enhancement Small Molecule
PF-07258669
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Melanocortin-4 receptor (MC4R) Antagonist
Anorexia Phase 1 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1 Inhibitor
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
PF-07038124
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical PDE4 Inhibitor
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
PF-07242813
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
CD1a inhibitor
Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity Biologic
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK1 Inhibitor
Go to clinical trial
Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.) Registration New Molecular Entity Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinase inhibitor andMEK inhibitor and anti PD-1
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma Phase 3 Product Enhancement Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-07104091
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK2 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule